Currently, prostate cancer is most commonly clinically diagnosed by detecting the prostate-specific antigen (PSA); however, this method may miss some aggressive prostate cancers, and the diagnosis of prostate cancer requires new biomarkers [110]. This evidence concerns the gene KLK3 and prostate carcinoma.